278 related articles for article (PubMed ID: 35159185)
1. Mast Cells in Immune-Mediated Cholangitis and Cholangiocarcinoma.
González MI; Vannan DT; Eksteen B; Flores-Sotelo I; Reyes JL
Cells; 2022 Jan; 11(3):. PubMed ID: 35159185
[TBL] [Abstract][Full Text] [Related]
2. Precancerous bile duct pathology in end-stage primary sclerosing cholangitis, with and without cholangiocarcinoma.
Lewis JT; Talwalkar JA; Rosen CB; Smyrk TC; Abraham SC
Am J Surg Pathol; 2010 Jan; 34(1):27-34. PubMed ID: 19898228
[TBL] [Abstract][Full Text] [Related]
3. Cholangiocytes in the pathogenesis of primary sclerosing cholangitis and development of cholangiocarcinoma.
Chung BK; Karlsen TH; Folseraas T
Biochim Biophys Acta Mol Basis Dis; 2018 Apr; 1864(4 Pt B):1390-1400. PubMed ID: 28844951
[TBL] [Abstract][Full Text] [Related]
4. Beneficial autoimmunity links primary biliary cholangitis to the avoidance of cholangiocarcinoma.
Pol JG; Paillet J; Plantureux C; Kroemer G
Oncoimmunology; 2021; 10(1):1968595. PubMed ID: 34527429
[TBL] [Abstract][Full Text] [Related]
5. Distinct immune surveillance in primary biliary cholangitis and primary sclerosing cholangitis is linked with discrete cholangiocarcinoma risk.
Nanjundappa RH; Christen U; Umeshappa CS
Hepatol Commun; 2023 Sep; 7(9):. PubMed ID: 37555943
[TBL] [Abstract][Full Text] [Related]
6. Genetic and epigenetic abnormalities in primary sclerosing cholangitis-associated cholangiocarcinoma.
Timmer MR; Beuers U; Fockens P; Ponsioen CY; Rauws EA; Wang KK; Krishnadath KK
Inflamm Bowel Dis; 2013 Jul; 19(8):1789-97. PubMed ID: 23615529
[TBL] [Abstract][Full Text] [Related]
7. Diagnostic yield of bile duct brushings for cholangiocarcinoma in primary sclerosing cholangitis: a systematic review and meta-analysis.
Trikudanathan G; Navaneethan U; Njei B; Vargo JJ; Parsi MA
Gastrointest Endosc; 2014 May; 79(5):783-9. PubMed ID: 24140129
[TBL] [Abstract][Full Text] [Related]
8. Biliary dysplasia, cell proliferation and nuclear DNA-fragmentation in primary sclerosing cholangitis with and without cholangiocarcinoma.
Bergquist A; Glaumann H; Stål P; Wang GS; Broomé U
J Intern Med; 2001 Jan; 249(1):69-75. PubMed ID: 11168786
[TBL] [Abstract][Full Text] [Related]
9. An animal model of benign bile-duct stricture, sclerosing cholangitis and cholangiocarcinoma and the role of epidermal growth factor receptor in ductal proliferation.
Cheifetz RE; Davis NL; Owen DA
Can J Surg; 1996 Jun; 39(3):193-7. PubMed ID: 8640617
[TBL] [Abstract][Full Text] [Related]
10. Diagnosis of cholangiocarcinoma in primary sclerosing cholangitis.
Taghavi SA; Eshraghian A; Niknam R; Sivandzadeh GR; Bagheri Lankarani K
Expert Rev Gastroenterol Hepatol; 2018 Jun; 12(6):575-584. PubMed ID: 29781738
[TBL] [Abstract][Full Text] [Related]
11. Cholangiocarcinoma cell proliferation is enhanced in primary sclerosing cholangitis: A role for IL-17A.
Lieshout R; Kamp EJCA; Verstegen MMA; Doukas M; Dinjens WNM; Köten K; IJzermans JNM; Bruno MJ; Peppelenbosch MP; van der Laan LJW; de Vries AC
Int J Cancer; 2023 Jun; 152(12):2607-2614. PubMed ID: 36346104
[TBL] [Abstract][Full Text] [Related]
12. Biliary dysplasia in primary sclerosing cholangitis harbors cytogenetic abnormalities similar to cholangiocarcinoma.
Kerr SE; Barr Fritcher EG; Campion MB; Voss JS; Kipp BR; Halling KC; Lewis JT
Hum Pathol; 2014 Sep; 45(9):1797-804. PubMed ID: 25027853
[TBL] [Abstract][Full Text] [Related]
13. Surveillance of primary sclerosing cholangitis with ERC and brush cytology: risk factors for cholangiocarcinoma.
Boyd S; Mustonen H; Tenca A; Jokelainen K; Arola J; Färkkilä MA
Scand J Gastroenterol; 2017 Feb; 52(2):242-249. PubMed ID: 27806633
[TBL] [Abstract][Full Text] [Related]
14. MR Imaging in Primary Sclerosing Cholangitis and Other Cholangitis.
O'Brien C; Malik M; Jhaveri K
Radiol Clin North Am; 2022 Sep; 60(5):843-856. PubMed ID: 35989048
[TBL] [Abstract][Full Text] [Related]
15. Diagnostic benefit of biliary brush cytology in cholangiocarcinoma in primary sclerosing cholangitis.
Boberg KM; Jebsen P; Clausen OP; Foss A; Aabakken L; Schrumpf E
J Hepatol; 2006 Oct; 45(4):568-74. PubMed ID: 16879890
[TBL] [Abstract][Full Text] [Related]
16. Mast Cell and Innate Immune Cell Communication in Cholestatic Liver Disease.
Bernard JK; Marakovits C; Smith LG; Francis H
Semin Liver Dis; 2023 May; 43(2):226-233. PubMed ID: 37268012
[TBL] [Abstract][Full Text] [Related]
17. Clinical clues to suspicion of IgG4-associated sclerosing cholangitis disguised as primary sclerosing cholangitis or hilar cholangiocarcinoma.
Oh HC; Kim MH; Lee KT; Lee JK; Moon SH; Song TJ; Eum J; Park DH; Lee SS; Seo DW; Lee SK
J Gastroenterol Hepatol; 2010 Dec; 25(12):1831-7. PubMed ID: 21091993
[TBL] [Abstract][Full Text] [Related]
18. Epidemiology of cholangiocarcinoma.
Bergquist A; von Seth E
Best Pract Res Clin Gastroenterol; 2015 Apr; 29(2):221-32. PubMed ID: 25966423
[TBL] [Abstract][Full Text] [Related]
19. Cholangioscopy with narrow-band imaging in patients with primary sclerosing cholangitis undergoing ERCP.
Azeem N; Gostout CJ; Knipschield M; Baron TH
Gastrointest Endosc; 2014 May; 79(5):773-779.e2. PubMed ID: 24206748
[TBL] [Abstract][Full Text] [Related]
20. [Gastrointestinal endoscopy in the diagnosis and treatment of biliary liver disease].
Liang XY; Ding HG
Zhonghua Gan Zang Bing Za Zhi; 2022 Jul; 30(7):690-695. PubMed ID: 36038336
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
